Shares of Synlogic, Inc. (NASDAQ:SYBX – Get Rating) have been given a consensus recommendation of “Buy” by the six brokerages that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $8.00.
A number of equities research analysts have recently weighed in on SYBX shares. HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of Synlogic in a research report on Monday. SVB Leerink dropped their price objective on Synlogic from $11.00 to $8.00 and set an “outperform” rating for the company in a report on Friday, March 18th. Zacks Investment Research downgraded Synlogic from a “buy” rating to a “hold” rating in a report on Friday. Finally, Oppenheimer dropped their price objective on Synlogic from $7.00 to $6.00 in a report on Thursday, May 12th.
Synlogic stock opened at $1.21 on Tuesday. The firm has a market cap of $85.00 million, a P/E ratio of -1.21 and a beta of 1.56. The business’s fifty day moving average is $1.87 and its two-hundred day moving average is $2.10. Synlogic has a 52 week low of $1.02 and a 52 week high of $4.54.
A number of large investors have recently added to or reduced their stakes in SYBX. Laurion Capital Management LP bought a new position in shares of Synlogic during the third quarter worth approximately $244,000. RA Capital Management L.P. bought a new position in shares of Synlogic during the third quarter worth approximately $20,333,000. Franklin Resources Inc. bought a new position in shares of Synlogic during the third quarter worth approximately $310,000. Raymond James & Associates bought a new position in shares of Synlogic during the third quarter worth approximately $34,000. Finally, Suvretta Capital Management LLC bought a new position in shares of Synlogic during the third quarter worth approximately $183,000. Hedge funds and other institutional investors own 62.15% of the company’s stock.
About Synlogic (Get Rating)
Synlogic, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria.
- Get a free copy of the StockNews.com research report on Synlogic (SYBX)
- CrowdStrike: A Cybersecurity Unicorn
- Time to Bid Low for Farfetch Stock
- Texas Roadhouse Stock Looks Sizzling Down Here
- Two Stocks You Shouldn’t Buy On Post-Earnings Weakness
- Don’t Wait Too Long to Buy These 3 Mega Caps
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.